Biweekly Intraperitoneal Oxaliplatin With Systemic Capecitabine and Bevacizumab for Patients With Peritoneal Carcinomatosis From Appendiceal or Colorectal Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 10, 2011

Primary Completion Date

September 27, 2026

Study Completion Date

September 27, 2026

Conditions

Carcinoma

Interventions

DRUG

Intraperitoneal Oxaliplatin

DRUG

Bevacizumab

DRUG

Capecitabine

Trial Locations (1)

Washington University School of Medicine, St Louis

All Listed Sponsors

lead

Washington University School of Medicine

OTHER